The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021- 022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins

Endocrinology

Volumn 140, Issue 3, 1999, Pages 1449-1458

  Wagner, B L ^a   Pollio, G ^a   Giangrande, P ^a   Webster, J C ^e   Breslin, M ^b   Mais, D E ^c   Cook, C E ^e   Vedeckis, W V ^b   Cidlowski, J A ^e   McDonnell, D P ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; DNA; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; RTI 2207 222; RTI 2207 225; RTI 2207 226; RTI 3021 002; RTI 3021 003; RTI 3021 012; RTI 3021 020; RTI 3021 021; RTI 3021 022; RTI 3021 023; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0032959038     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.3.6581     Document Type: Article

References (41)

1. 1. Clark JH, Peck EJ 1979 Female Sex Steroids: Receptors and Function, ed 1. Springer-Verlag, New York, vol 14
2. 2. Clarke CL, Sutherland RL 1990 Progestin regulation of cellular proliferation. Endocr Rev 11:266-301
3. 3. Poisson M, Pertuiset BF, Hauw JJ, Philippon J, Buge A, Moguilewsky M, Philibert D 1983 Steroid hormone receptors in human meningiomas, gliomas and brain metastases. J Neurooncol 1:179-189
4. 4. Brandon DB, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington BS, Erickson TE, Warner C, Keenan EJ, Clinton GM 1993 Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169:78-85
5. 5. Carroll RS, Glowacka D, Dashner K, Black PM 1993 Progesterone receptors in meningiomas. Cancer Res 53:1312-1316
6. 6. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB 1991 The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 87:277-283
7. 7. Horwitz KB 1992 The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer. Endocr Rev 13:146-163
8. 8. Lundgren S 1992 Progestins in breast cancer treatment. Acta Oncol 31:709-722
9. 9. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SS 1991 Endocrine responses to long-term administration of the anti-progesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56:402-407
10. 10. Philibert D, Costerousse G, Gaillard-Moguilewsky M, Nedelec L, Nique F, Tournemine C, Teutsch G 1991 From RU 38486 towards dissociated antiglucocorticoid and antiprogesterone. Front Horm Res 19:1-17
11. 11. Baulieu E-E 1989 Contragestation and other clinical applications of RU486, an antiprogesterone at the receptor. Science 245:1351-1357
12. 12. Donaldson MS, Dorflinger L, Brown SS, Benet LZ 1993 Clinical Applications of Mifepristone (RU486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda. National Academy Press, Washington, DC
13. 13. Teutsch G, Nique F, Lemoine G, Bouchoux F, Cerede E, Gofflo D, Philibert D 1995 General Structure-Activity Correlations of Antihormones. New York Academy Press, New York, vol 761
14. 14. Teutsch G, Gaillard-Moguilewsky M, Lemoine G, Nique F, Philibert D 1991 Design of ligands for the glucocorticoid and progestin receptors. Biochem Soc Trans 19:901-908
15. 15. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713
16. 16. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP 1993 Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244-1255
17. 17. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP 1998 The nuclear corepressors NCoR and SMRT are key regulators of both ligand and 8-Bromo-cAMP dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18:1369-1378
18. 18. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY-W, Imhof MO, Edwards DP, Cook CE, McDonnell DP 1996 16α-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 93:8739-8744
19. 19. Di Lorenzo D, Albertini A, Zava D 1991 Progestin regulation of alkaline phosphatase in the human breast cancer cell line T47D. Cancer Res 51:4470-4475
20. 20. Norris J, Fan D, Aleman C, Marks JR, Futreal A, Wiseman RW, Iglehart JD, Deininger PL, McDonnell DP 1995 Identification of a new subclass of alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 270:22777-22782
21. 21. Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA 1997 Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 272:9287-9293
22. 22. McDonnell DP, Clemm DL, Herman T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
23. 23. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30
24. 24. El-Ashry D, Oñate S, Nordeen S, Edwards D 1989 Human progesterone receptor complexed with the antagonist RU486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558
25. 25. Gronemeyer H 1992 Control of transcription activation by steroid hormone receptors. FASEB J 6:2524-2529
26. 26. Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai M-J, O'Malley BW 1991 Anti-estrogen can establish non-productive complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 88:3125-3129
27. 27. Nazareth LV, Harbour DV, Thompson EB 1991 Mapping the human glucocorticoid receptor for leukemic cell death. J Biol Chem 266:12976-12980
28. 28. Helmberg A, Auphan N, Caelles C, Karin M 1995 Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 14:452-460
29. 29. Barrett TJ, Vig E, Vedeckis WV 1996 Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down-and up-regulation. Biochemistry 35:9746-9753
30. 30. Zhou F, Thompson EB 1996 Role of c-jun induction in the glucocorticoid-evoked apoptotic pathway in human leukemic lymphoblasts. Mol Endocrinol 10:306-316
31. 31. Dana SL, Hoener PA, Wheeler DL, Lawrence CL, McDonnell DP 1994 Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol Endocrinol 8:1193-1207
32. 32. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10:119-131
33. 33. Meyer M-E, Gronemeyer H, Turcotte B, Bocquel M-T, Tasset D, Chambon P 1989 Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57:433-442
34. 34. Nordeen SK, Bona BJ, Beck CA, Edwards DP, Borror KC, DeFranco DB 1995 The two faces of a steroid antagonist: when an antagonist isn't. Steroids 60:97-104
35. 35. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independant repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-403
36. 36. Chen DJ, Umesono K, Evans RM 1996 SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc Natl Acad Sci USA 93:7567-7571
37. 37. Alland L, Muhle R, Hou HJ, Potes J, Chin L, Schreiber-Agus N, DePinho RA 1997 Role of N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49-55
38. 38. Heinzel T, Lavinsky RM, Mullen T-M, Soderstrom M, Laherty CD, Torchia J, Yang W-M, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48
39. 39. Nagy L, Kao H-Y, Chakravarti D, Lin RJ, Hassing CA, Ayer DE, Schreiber SL, Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380
40. 40. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
41. 41. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705